Foghorn Therapeutics Inc Ordinary Shares FHTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $3.74
- Day Range
- $3.62–3.80
- 52-Week Range
- $3.27–6.95
- Bid/Ask
- $3.63 / $3.93
- Shares Outstanding
- 58.71M
- Market Cap
- $219.00M
- Volume/Avg
- 118,963 / 157,020
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 8.54
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 106
- Website
- https://www.foghorntx.com
Valuation
|
Metric
|
FHTX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 8.54 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
FHTX
|
|---|---|
Quick Ratio | 2.85 |
Current Ratio | 2.92 |
Interest Coverage | — |
Quick Ratio
FHTX
Profitability
|
Metric
|
FHTX
|
|---|---|
Return on Assets (Normalized) | −27.45% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
FHTX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Wsrwdqpj | Jkkwbnx | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Qfxvqknwm | Jsbpvq | $67B | |||
| argenx SE ADR
ARGX
| Xbpnmmm | Xgdz | $55B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Gxmhjdvs | Rynnkw | $40B | |||
| Royalty Pharma PLC Class A
RPRX
| Bsrdqxsj | Yvdbwmq | $25B | |||
| BioNTech SE ADR
BNTX
| Cdhpjdjd | Wmmnr | $22B | |||
| Incyte Corp
INCY
| Sfphrgwpv | Rrdn | $20B | |||
| Moderna Inc
MRNA
| Lywzbjpg | Npr | $19B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Twwpdvqb | Fhgfq | $15B | |||
| BridgeBio Pharma Inc
BBIO
| Kmtjjrlv | Kyd | $13B |
United States